Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease
Mette V. Østergaard, Thomas Secher, Michael Christensen, Casper Gravesen Salinas, Urmas Roostalu, Jacob Lercke Skytte, Ida Rune, Henrik H. Hansen, Jacob Jelsing, Niels Vrang, Lisbeth N. Fink
Abstract
Translational animal models of diabetic kidney disease (DKD) are important tools in preclinical research and drug discovery. Here, we show that the standard of care to control hypertension (lisinopril) and hyperglycemia (empagliflozin) improves physiological and histopathological hallmarks of kidney disease in a mouse model of hypertension-accelerated progressive DKD. The findings substantiate hypertension and type 2 diabetes as essential factors in driving DKD progression and provide a proof of concept for probing novel drugs for potential nephroprotective efficacy in this model.